Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11279796 | 1.00 | LMNA (0.50) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11741360 | 0.78 | LMNA (0.61) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL10459087 | 0.74 | ASAH1 (0.72) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11241994 | 0.74 | LMNA (0.43) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11241987 | 0.74 | LMNA (0.43) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11241981 | 0.73 | CYP2D6 (0.43) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11241986 | 0.73 | CYP2D6 (0.43) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11258729 | 0.73 | MEN1 (0.43) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL11238672 | 0.73 | MEN1 (0.43) | LMNACYP3A4CYP2D6MAPK3ASAH1 | |
| SCHEMBL10459041 | 0.73 | LMNA (0.56) | LMNACYP3A4CYP2D6MAPK3ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4349552-A | TREATMENT OF CANCER | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |